Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $411.47 | 6 | 69.3% |
| Food and Beverage | $181.92 | 4 | 30.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $411.47 | 6 | $0 (2022) |
| ViiV Healthcare Company | $124.44 | 1 | $0 (2024) |
| ABBVIE INC. | $22.89 | 1 | $0 (2024) |
| Eisai Inc. | $18.23 | 1 | $0 (2021) |
| AIMMUNE THERAPEUTICS, INC. | $16.36 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $163.69 | 3 | ViiV Healthcare Company ($124.44) |
| 2022 | $178.99 | 2 | Astellas Pharma US Inc ($178.99) |
| 2021 | $126.72 | 3 | Astellas Pharma US Inc ($108.49) |
| 2018 | $99.00 | 1 | Astellas Pharma US Inc ($99.00) |
| 2017 | $24.99 | 1 | Astellas Pharma US Inc ($24.99) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: GI | ||||||
| 09/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $124.44 | General |
| Category: HIV | ||||||
| 02/02/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/08/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 08/08/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 11/03/2021 | Eisai Inc. | Fycompa (Drug) | Food and Beverage | Cash or cash equivalent | $18.23 | General |
| Category: Neurology | ||||||
| 09/02/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $77.00 | General |
| 09/02/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $31.49 | General |
| 07/25/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 05/05/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $24.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 2,034 | 176,421 | $1.6M | $410,825 |
| 2022 | 23 | 2,042 | 212,709 | $1.7M | $453,713 |
| 2021 | 21 | 2,025 | 188,780 | $1.6M | $424,154 |
| 2020 | 21 | 1,973 | 232,191 | $1.7M | $508,491 |
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 830 | 1,509 | $445,155 | $144,628 | 32.5% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 29 | 9,000 | $279,000 | $106,196 | 38.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 161 | 928 | $208,800 | $45,661 | 21.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 177 | 350 | $134,369 | $33,782 | 25.1% |
| 96521 | Refilling and maintenance of portable pump | Office | 2023 | 46 | 145 | $54,375 | $13,986 | 25.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 139 | 155 | $41,075 | $9,897 | 24.1% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 32 | 33 | $14,850 | $7,219 | 48.6% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 44 | 45 | $16,875 | $7,212 | 42.7% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 41 | 159,436 | $183,794 | $6,374 | 3.5% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 44 | 556 | $43,090 | $5,909 | 13.7% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 36 | 43 | $10,750 | $5,301 | 49.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $17,728 | $3,996 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 26 | $14,151 | $3,634 | 25.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 16 | 128 | $11,965 | $2,860 | 23.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 42 | 53 | $14,453 | $2,817 | 19.5% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 25 | 31 | $5,270 | $2,635 | 50.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $8,715 | $2,289 | 26.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $7,374 | $1,609 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 14 | $3,818 | $1,005 | 26.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 42 | 2,364 | $84,060 | $975.28 | 1.2% |
| J0692 | Injection, cefepime hydrochloride, 500 mg | Office | 2023 | 42 | 738 | $31,890 | $722.91 | 2.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 47 | 74 | $1,480 | $621.60 | 42.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 15 | 15 | $1,275 | $616.80 | 48.4% |
| 11000 | Removal of inflamed or infected skin, up to 10% of body surface | Facility | 2023 | 19 | 23 | $2,300 | $503.93 | 21.9% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 86 | 670 | $10,050 | $340.66 | 3.4% |
About Dr. Roberto Mercado, MD
Dr. Roberto Mercado, MD is a Infectious Disease healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073610515.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roberto Mercado, MD has received a total of $593.39 in payments from pharmaceutical and medical device companies, with $163.69 received in 2024. These payments were reported across 10 transactions from 5 companies. The most common payment nature is "Education" ($411.47).
As a Medicare-enrolled provider, Mercado has provided services to 8,074 Medicare beneficiaries, totaling 810,101 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Sarasota, FL
- Active Since 09/19/2006
- Last Updated 11/22/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1073610515
Products in Payments
- DOVATO (Drug) $124.44
- AVYCAZ (Drug) $22.89
- Fycompa (Drug) $18.23
- VOWST (Biological) $16.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Sarasota
Dr. Lavinia Suciu, M.d, M.D
Infectious Disease — Payments: $6,987
Andrew Krinsky, Md, MD
Infectious Disease — Payments: $6,044
Manuel Gordillo, Md, MD
Infectious Disease — Payments: $3,558
Rishi Bhattacharyya, Md, MD
Infectious Disease — Payments: $2,529
Natan Kraitman, M.d, M.D
Infectious Disease — Payments: $1,877
Sudha Tallapragada, Md, MD
Infectious Disease — Payments: $1,461